Love Pharma Inc. (CSE: LUV) (FSE: G1Q0) an international sexual health, wellness, and psychedelics company, launches its first two products, BLOOM™ and AURALIEF™.

Zachary Stadnyk, CEO, stated: "It is with great excitement that we are able to announce the launch of our first two fully-branded products, Bloom and Auralief. We believe these two products within our strong portfolio of intellectual property can quickly command significant market share in the shortest period. We look forward to updating our investors as we progress through the rollout of these first two products and subsequently, the company's therapeutic and wellness products in a strategic, staggered approach."

For more information, please view the InvestmentPitch Media "video" which provides additional information about this news. If this link is not enabled, please visit and enter "Love Pharma" in the search box.

BLOOM™ is a topical female arousal gel providing increased lubrication and sensitivity that arouses the user, thereby addressing issues of female sexual disfunction. It is also designed to be sold as an over-the counter product without CBD or THC.

AURALIEF™, an oral muco-adhesive sublingual strip, infused with THC and/or CBD, enhances the bioavailability of THC and CBD, thereby increasing the impact of its health elements. By delivering THC and CBD into the system more quickly and efficiently than conventional methods it expedites and enhances the beneficial effects of THC and CBD within the body.

Joshua Maurice, COO, added: "Bringing any product to market is exciting, and with BLOOM™-our exclusive formula proven to enhance women's arousal we're excited for our new branded launch."

Founded in 2020, Love Pharma is focused on the Global Sexual Health, Wellness, and Psychedelics markets, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America. The company has a number of other proven products in the pipeline to aid in mental and sexual health and wellness.

The company is also actively seeking additional mergers and acquisitions to complement its strong portfolio of intellectual property.

The shares which began trading on the CSE on September 30, are trading at $0.065. For more information, please visit the company's website, contact Zach Stadnyk, President and CEO, at 604-343-2977 or toll free at 1-833-604-LOVE (5683) or by email at

About InvestmentPitch Media

Investmentpitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.


InvestmentPitch Media
Barry Morgan, CFO

To view the source version of this press release, please visit

News Provided by Newsfile via QuoteMedia

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

  • Bivalent vaccine authorized as third 3-µg dose in the three-dose primary series
  • Consistent COVID-19 hospitalization rates in this age group coupled with an overall surge in respiratory illnesses among children under 5 in the United States creates urgent need to make updated COVID-19 vaccines available
  • Doses to ship immediately upon recommendation by CDC

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age. Children in this age group can receive a primary series consisting of two 3-µg doses of the original Pfizer-BioNTech COVID-19 Vaccine followed by a third 3-µg dose of the bivalent vaccine to complete the primary series. Vaccine doses can be delivered immediately upon receipt of a recommendation from the U.S. Centers for Disease Control and Prevention ("CDC").

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

BetterLife Announces Closing of Private Placement

BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR  OTCQB : BETRF FRA: NPAU ) is pleased to announce that it has closed a non-brokered private placement (the "Offering") by issuing 3,160,000 common shares at a price of USD$0.15 per common share for gross proceeds of USD$474,000. The common shares issued pursuant to the Offering are subject to a hold period under applicable securities laws, which hold period expires four months and a day following the date of issuance. BetterLife will use the proceeds for working capital purposes and for advancement of pre-clinical and clinical programs. Negev Capital and certain European-based investors participated in the Offering.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer's Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults

If approved, RSVpreF would help address the substantial burden of RSV disease in individuals 60 years of age or older

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate, PF-06928316 or RSVpreF, as submitted for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
teal and white pills over pink background

Top 10 Pharma Companies by Revenue (Updated 2022)

The pharmaceutical industry is the cornerstone of drug development, commercialization and marketing.

According to Statista, pharma sector revenue topped US$1 trillion for the first time in 2014, and has steadily increased since then to reach US$1.42 trillion in 2021. North America is the largest growth segment thanks to the behemoth US pharmaceutical industry. In terms of prescription drugs alone, Evaluate Pharma estimates that sales will reach US$1 trillion by 2026.

So which companies are responsible for the most growth and innovation in the pharma space?

Keep reading...Show less
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease

Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease

  • Agreement aims to advance discovery and development of novel papain-like protease (PLpro) inhibitors and potentially introduce a new class of oral antivirals in the fight against COVID-19
  • Expands Pfizer's innovative anti-infective pipeline, complementing the company's existing portfolio of COVID-19 products

Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19. PLpro is an essential enzyme, which, along with the main protease (Mpro), plays an important role in viral replication. This program will expand Pfizer's innovative anti-infective pipeline and, if successful, will complement Pfizer's existing portfolio of COVID-19 products with direct-acting antiviral agents against different SARS-CoV-2 targets.

This press release features multimedia. View the full release here:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. , Imago BioSciences, Inc. , Opiant Pharmaceuticals Inc. , Benefitfocus, Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( ) or Marc Ackerman ( ) at 855-576-4847. There is no cost or financial obligation to you.

Apollo Endosurgery, Inc. (Nasdaq - APEN)

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News